Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
Institute of Neuroradiology, University Hospitals Schleswig-Holstein, Campus Lübeck, Luebeck, Germany.
J Neurointerv Surg. 2023 Nov;15(11):1111-1116. doi: 10.1136/jnis-2022-019859. Epub 2023 Jan 6.
Endovascular embolization is a feasible treatment for cranial dural arteriovenous fistulas (DAVFs). New embolic agents aim to improve the success of DAVF embolization.
To assess the safety, efficacy, and short-term outcome of the treatment of DAVFs using the new liquid embolic agent Squid.
The LIQUID study is a prospective, observational multicenter study on the treatment of high-grade (Cognard type ≥3) DAVFs with the embolic agent Squid. The primary outcome measures were safety (ie, morbidity and mortality), as well as the occlusion rate 90 to 180 days after treatment.
In eight centers, 53 patients (mean age 59.8 years, 22.6% female) were treated in 55 treatment sessions. Of the DAVFs, 56.6% were Cognard type III, 41.5% type IV, and 18.9% were ruptured. Squid 18 was used in 83.6% and Squid 12 in 32.7% of the treatments. The overall rate of intraprocedural or postprocedural adverse events (AEs) was 18.2%. Procedure-related AEs resulting in permanent morbidity were observed in 3.6%. One patient (1.8%) died unrelated to the procedure due to pulmonary embolism. The final complete occlusion rate at 90 to 180 days was 93.2%. After a mean follow-up of 5.5 months, the modified Rankin Scale (mRS) score was stable or improved in 93.0%. In one of the patients, worsening of the mRS score was related to the procedure (1.8%).
Squid is a safe and effective liquid embolic agent for the treatment of high-grade DAVFs.
血管内栓塞是治疗颅腔硬脑膜动静脉瘘（DAVF）的一种可行方法。新型栓塞剂旨在提高 DAVF 栓塞的成功率。
评估新型液体栓塞剂 Squid 治疗 DAVF 的安全性、疗效和短期结果。
LIQUID 研究是一项前瞻性、多中心研究，旨在使用 Squid 栓塞剂治疗高分级（Cognard 分级≥3）DAVF。主要观察指标为安全性（即发病率和死亡率）以及治疗后 90 至 180 天的闭塞率。
在 8 个中心，53 例患者（平均年龄 59.8 岁，22.6%为女性）在 55 次治疗中接受了治疗。DAVF 中，Cognard 分级Ⅲ型占 56.6%，Ⅳ型占 41.5%，破裂占 18.9%。Squid 18 在 83.6%的治疗中使用，Squid 12 在 32.7%的治疗中使用。术中或术后不良事件（AE）的总发生率为 18.2%。观察到 3.6%的与操作相关的永久性并发症导致发病率。1 例患者（1.8%）因肺栓塞与操作无关而死亡。90 至 180 天的最终完全闭塞率为 93.2%。平均随访 5.5 个月后，93.0%的改良 Rankin 量表（mRS）评分稳定或改善。在 1 例患者中，mRS 评分的恶化与操作相关（1.8%）。
Squid 是一种安全有效的治疗高分级 DAVF 的液体栓塞剂。
Zotero 插件